UnknownPhase 2/3

Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba

Lebanon40 participantsStarted 2019-03-01

Plain-language summary

Pityriasis alba (PA) is a common benign skin disorder, that usually affects children and adolescents of darker phototypes. A history of atopic dermatitis is a well-known risk factor, and PA may be a minor manifestation of atopic dermatitis, although it can occur in nonatopic individuals as well. The objective is to evaluate the effect of topical pimecrolimus in the treatment of treatment of PA

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pityriasis alba Patients confirmed by a board certified dermatologist * Age over 2 years * Written informed consent signed by the patients or the legal guardians of patients younger than 18 years in the native language (Arabic) Exclusion Criteria: * Other concomitant dermatosis (except atopic dermatitis) * Use of topical steroids, or topical agents other than emollients and sunscreen, in the last 4 weeks * Known allergy to pimecrolimus * Pregnant and nursing women

What they're measuring

Percentage of repigmentation of index lesions

Timeframe: 9 weeks

Trial details

NCT IDNCT03834935

SponsorSt Joseph University, Beirut, Lebanon

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-02-01

Contact for this trial

elio G kechichian, MD

+9613079072 elio.kechichian@gmail.com

View on ClinicalTrials.gov More Pityriasis Alba trials